Search

Your search keyword '"Oneto, R."' showing total 151 results
Start Over Author "Oneto, R."
151 results on '"Oneto, R."'

5. Identification of prognostic factors predicting outcome in Hodgkinʼs lymphoma patients relapsing after autologous stem cell transplantation†

Author

Martínez, C., Canals, C., Sarina, B., Alessandrino, E. P., Karakasis, D., Pulsoni, A., Sica, S., Trneny, M., Snowden, J. A., Kanfer, E., Milpied, N., Bosi, A., Guidi, S., de Souza, C. A., Willemze, R., Arranz, R., Jebavy, L., Hellmann, A., Sibon, D., Oneto, R., Luan, J. J., Dreger, P., Castagna, L., and Sureda, A.

Published
2013
Full Text
View/download PDF

12. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients

Author

Rambaldi, A, Bacigalupo, A, Fanin, R, Ciceri, F, Bonifazi, F, Falda, M, Lambertenghi-Deliliers, G, Benedetti, F, Bruno, B, Corradini, P, Alessandrino, P E, Iacopino, P, Arcese, W, Scimè, R, Raimondi, R, Sica, S, Castagna, L, Lamparelli, T, Oneto, R, Lombardini, L, Pollichieni, S, Algarotti, A, Carobbio, A, Sacchi, N, and Bosi, A

Published
2012
Full Text
View/download PDF

24. Prospective study of rabbit antithymocyte globulin and ciclosporin for aplastic anemia from the EBMT Severe Aplastic Anemia Working Party

Author

Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, Al Zahrani HA, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G., RISITANO, ANTONIO MARIA, Marsh, Jc, Bacigalupo, A, Schrezenmeier, H, Tichelli, A, Risitano, ANTONIO MARIA, Passweg, Jr, Killick, Sb, Warren, Aj, Foukaneli, T, Aljurf, M, Al Zahrani, Ha, Schafhausen, P, Roth, A, Franzke, A, Brummendorf, Th, Dufour, C, Oneto, R, Sedgwick, P, Barrois, A, Kordasti, S, Elebute, Mo, Mufti, Gj, and Socie, G.

Published
2012

25. Bone marrow versus peripheral blood sibling transplants in acquired aplastic anemia: survival advantage for marrow in all age groups

Author

Bacigalupo A, Socie' G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuhrer M, Dufour C, Passweg J, Oneto R, Aljurf M, Flynn C, Mialou V, Hamladji RM, Marsh J., RISITANO, ANTONIO MARIA, Bacigalupo, A, Socie', G, Schrezenmeier, H, Tichelli, A, Locasciulli, A, Fuhrer, M, Risitano, ANTONIO MARIA, Dufour, C, Passweg, J, Oneto, R, Aljurf, M, Flynn, C, Mialou, V, Hamladji, Rm, and Marsh, J.

Published
2012

26. Rabbit ATG for aplastic anaemia treatment: a backward step?

Author

European Blood, Marrow Transplant Group, Severe Aplastic Anaemia Working P.a.r.t.y. Dufour C, Bacigalupo A, Oneto R, Socie G, Tichelli A, Passweg JR, Schrezenmeier H, Locasciulli A, Aljurf M, Marsh J.C., RISITANO, ANTONIO MARIA, European, Blood, Marrow Transplant, Group, Dufour C, Severe Aplastic Anaemia Working P. a. r. t. y., Bacigalupo, A, Oneto, R, Socie, G, Tichelli, A, Passweg, Jr, Risitano, ANTONIO MARIA, Schrezenmeier, H, Locasciulli, A, Aljurf, M, and Marsh, J. C.

Subjects
business.industry, Anemia, Aplastic, General Medicine, Prognosis, Molecular biology, Risk Assessment, Sensitivity and Specificity, Severity of Illness Index, Survival Analysis, Treatment Outcome, Cyclosporine, Medicine, Animals, Humans, Rabbits, Rabbit ATG, business, Immunosuppressive Agents, Antilymphocyte Serum, Randomized Controlled Trials as Topic
Published
2011

27. Limited chronic graft-versus-host disease is associated with better survival after alternative donor transplants for haematological malignancies: a retrospective GITMO analysis

Author

Crocchiolo, R., Ciceri, F., Teresa Lamparelli, Oneto, R., Bruno, B., Sormani, M. P., Fanin, R., Bandini, G., Bosi, A., Rambaldi, A., Alessandrino, E., Falda, M., Bacigalupo, A., Crocchiolo, R, Ciceri, Fabio, Lamparelli, T, Oneto, R, Bruno, B, Sormani, Mp, Fanin, R, Bandini, G, Bosi, A, Rambaldi, A, Alessandrino, E, Falda, M, and Bacigalupo, A.

Published
2010

28. HLA-DPB1 T cell epitope 4-group matching is significantly predictive of survival after unrelated hematopoietic stem cell transplantation in onco-hematologic patients from Italy: an updated analysis

Author

Crocchiolo R, Oneto R, Bruno B, Pollichieni S, Sacchi N, Fanin R, Garbarino L, Miotti V, Bandini G, Bosi A, Zino E, Bacigalupo A, Fleischhauer K., CICERI , FABIO, Crocchiolo, R, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, Fabio, Zino, E, Bacigalupo, A, and Fleischhauer, K.

Published
2010

29. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo, R., Zino, E., Vago, L., Oneto, R., Bruno, B., Pollichieni, S., Sacchi, N., Sormani, M. P., Marcon, J., Lamparelli, T., Fanin, R., Garbarino, L., Miotti, V., Bandini, G., Bosi, A., Ciceri, F., Bacigalupo, A., Fleischhauer, K., Midollo Osseo Gruppo Italiano Trapianto, D. I., Terapia Cellulare, Cellule Staminali Ematopoietiche Cse E., Italian Bone Marrow Donor Registry Collaboratori, Scalari P., Bontempelli, M., Prinoth, O., Carcassi, C., Marceno, R., Porfirio, Rombola, G., Lombardo, Ferrioli, G., Poli, F., Scalamogna, M., Mazzi, B., Rossi, F., Mascaretti, L., Albergoni, Salvaneschi, L., Salvaneschi, M., Valentini, Nesci, S., Papola, F., Scatena, Mariotti, Perrone, Laurenti, Grammatico, Paola, Mariani, M., Favoino, B., Guizzardi, Pontiero, Leoni, P., Rambaldi, A., Casini, M., Angelucci, E., Baronciani, D., La Nasa, G., Milone, G., Guidi, S., Van Lint, M. T., Dini, G., Corradini, P., Milani, R., Morra, E., Marenco, P., Deliliers, Lambretenghi G., Onida, F., Marcatti, M., Castagna, L., Pioltelli, P., Selleri, C., Zanesco, L., Scime, R., Musso, M., Alessandrino, E. P., Locatelli, F., Visani, G., Di Bartolomeo, P., Papineschi, F., Favre, C., Iori, A. P., Foa, Roberto, Locasciulli, A., Majolino, I., Majolino, P., Leone, G., Arcese, W., Cerretti, R., Carella, A. M., Cascavilla, N., Lauria, F., Mazza, P., Cerno, M., Benedetti, F., Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Lamparelli, T, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, F, Bacigalupo, A, and Fleischhauer, K

Subjects
Adult, Disease-Free Survival, Donor Selection, Female, HLA-DRB1 Chains, Hematologic Neoplasms, Humans, Italy, Male, Middle Aged, Recurrence, Registries, Retrospective Studies, Risk Factors, Survival Rate, Transplantation, Homologous, Algorithms, HLA-DR Antigens, Hematopoietic Stem Cell Transplantation, Tissue Donors, Biochemistry, Immunology, Hematology, Cell Biology, Homologous, medicine.medical_treatment, Human leukocyte antigen, Hematopoietic stem cell transplantation, Medicine, Risk factor, Survival rate, Transplantation, HLA-DPB1, business.industry, Hazard ratio, Confidence interval, business, Settore MED/15 - Malattie del Sangue
Abstract

The importance of donor-recipient human leukocyte antigen (HLA)-DPB1 matching for the clinical outcome of unrelated hematopoietic stem cell transplantation (HSCT) is controversial. We have previously described an algorithm for nonpermissive HLA-DPB1 disparities involving HLA-DPB1*0901,*1001,*1701,*0301,*1401,*4501, based on T-cell alloreactivity patterns. By revisiting the immunogenicity of HLA-DPB1*02, a modified algorithm was developed and retrospectively tested in 621 unrelated HSCTs facilitated through the Italian Registry for onco-hematologic adult patients. The modified algorithm proved to be markedly more predictive of outcome than the original one, with significantly higher KaplanMeier probabilities of 2-year survival in permissive compared with nonpermissive transplantations (55% vs 39%, P = .005). This was the result of increased adjusted hazards of nonrelapse mortality (hazard ratio [HR] = 1.74; confidence interval [CI], 1.19-2.53; P = .004) but not of relapse (HR = 1.02; CI, 0.73-1.42; P = .92). The increase in the hazards of overall mortality by nonpermissive HLA-DPB1 disparity was similar in 10 of 10 (HR = 2.12; CI, 1.23-3.64; P = .006) and 9 of 10 allele-matched transplantations (HR = 2.21; CI, 1.28-3.80; P = .004), both in early-stage and in advanced-stage disease. These data call for revisiting current HLA matching strategies for unrelated HSCT, suggesting that searches should be directed up-front toward identification of HLA-DPB1 permissive, 10 of 10 or 9 of 10 matched donors. (Blood. 2009; 114:1437-1444) RI Porfirio, Berardino/I-1988-2012

Published
2009

30. Allotransplant after autologous haematopoietic stem cell transplantation relapse in aggressive lymphoma patients: update af a retrospective GITMO study

Author

Rigacci L, Bosi A, Puccini B, Corradini P, Castagna L, Cascavilla N, Milone G, Bacigalupo A, Scime R, Specchia G, Rambaldi A, Leoni P, Levis A, Guidi S, Bruno B, Oneto R, Fanin R., CICERI , FABIO, Rigacci, L, Bosi, A, Puccini, B, Corradini, P, Castagna, L, Cascavilla, N, Milone, G, Bacigalupo, A, Scime, R, Specchia, G, Rambaldi, A, Leoni, P, Ciceri, Fabio, Levis, A, Guidi, S, Bruno, B, Oneto, R, and Fanin, R.

Published
2009

31. Non-permissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo R, Zino E, Vago L, Oneto R, Bruno B, Pollicchieni S, Sacchi N, Sormani MP, Marcon J, Fanin R, Garbarino L, Miotti V, Bandini G, Bosi A, Bacigalupo A, Fleischhauer K., CICERI , FABIO, Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollicchieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, Fabio, Bacigalupo, A, and Fleischhauer, K.

Published
2009

33. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Author

Alessandrino, Ep, Porta, Mg, Malcovati, L, Jackson, Ch, Pascutto, C, Bacigalupo, A, Teresa van Lint, M, Falda, M, Bernardi, M, Onida, F, Guidi, S, Iori, Ap, Cerretti, R, Marenco, P, Pioltelli, P, Angelucci, E, Oneto, R, Ripamonti, F, Rambaldi, A, Bosi, A, Cazzola, M, Gruppo Italiano Trapianto di Midollo Osseo Levis, A, Bandini, G, Casini, M, Rossi, G, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Van Lint MT, Corradini, P, Milani, R, Morra, E, Lambertenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scime, R, Iannitto, E, Musso, M, Locatelli, F, Zecca, M, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Merli, F, Foa, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Fanin, R, Cerno, M, Bortolo, S, and Author information, Raimondi R.

Subjects
Oncology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Cohort Studies, Female, Humans, Male, Markov Chains, Middle Aged, Myelodysplastic Syndromes, Risk, Survival Analysis, Time Factors, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Hematology, Homologous, medicine.medical_specialty, Allogeneic transplantation, medicine.medical_treatment, Hematopoietic stem cell transplantation, Natural history of disease, Internal medicine, medicine, 80 and over, Survival analysis, Transplantation, business.industry, Myelodysplastic syndromes, Original Articles, medicine.disease, Settore MED/15, Surgery, allogeneic transplantation, International Prognostic Scoring System, Risk assessment, business
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferior overall survival. To define the optimal timing of allogeneic HSCT, we carried out a decision analysis by studying 660 patients who received best supportive care and 449 subjects who underwent transplantation. Risk assessment was based on both the International Prognostic Scoring System (IPSS) and the World Health Organization classification-based Prognostic Scoring System (WPSS). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of allogeneic HSCT on survival. This model estimated life expectancy from diagnosis according to treatment policy at different risk stages. Relative to supportive care, estimated life expectancy increased when transplantation was delayed from the initial stages until progression to intermediate-1 IPSS-risk or to intermediate WPSS-risk stage, and then decreased for higher risks. Modeling decision analysis on WPSS versus IPSS allowed better estimation of the optimal timing of transplantation. These observations indicate that allogeneic HSCT offers optimal survival benefits when the procedure is performed before MDS patients progress to advanced disease stages. Am. J. Hematol. 88:581–588, 2013. © 2013 Wiley Periodicals, Inc.

Published
2013

35. Fludarabine, cyclophosphamide, anti-thymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia (SAA): a retrospective study from the EBMT-SAA Working Party

Author

Bacigalupo, A, Socie', G, Lanino, E, Prete, A, Locatelli, F, Locasciulli, A, Cesaro, Simone, Shimoni, A, Marsh, J, Brune, M, van Lint MT, Oneto, R, and Passweg, J.

Subjects
Thymocyte globulin, alternative donor transplants, severe aplastic anemia
Published
2010

36. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Dufour, C., primary, Pillon, M., additional, Passweg, J., additional, Socie, G., additional, Bacigalupo, A., additional, Franceschetto, G., additional, Carraro, E., additional, Oneto, R., additional, Risitano, A. M., additional, de Latour, R. P., additional, Tichelli, A., additional, Rovo, A., additional, Peters, C., additional, Hoechsmann, B., additional, Samarasinghe, S., additional, Kulasekararaj, A. G., additional, Schrezenmeier, H., additional, Aljurf, M., additional, and Marsh, J., additional

Published
2014
Full Text
View/download PDF

37. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Lamparelli, T, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, F, Bacigalupo, A, Fleischhauer, K, Gruppo Italiano Trapianto di Midollo Osseo, Terapia Cellulare, Cellule Staminale Ematopoietiche e., Italian Bone Marrow Donor Registry, Scalari, P, Bontempelli, M, Prinoth, O, Carcassi, C, Marcenò, R, Porfirio, Rombolà, G, Lombardo, Ferrioli, G, Poli, F, Scalamogna, M, Mazzi, B, Rossi, F, Mascaretti, L, Albergoni, Salvaneschi, L, Martinetti, M, Valentini, Renzo, Nesci, S, Papola, F, Scatena, Mariotti, Perrone, Laurenti, Grammatico, P, Mariani, M, Favoino, B, Guizzardi, Pontiero, Leoni, P, Rambaldi, A, Casini, M, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Guidi, S, Van Lint MT, Dini, G, Corradini, P, Milani, R, Morra, E, Marenco, P, Lambretenghi Deliliers, G, Onida, F, Marcatti, M, Castagna, L, Pioltelli, P, Selleri, C, Zanesco, L, Scimè, R, Musso, M, Alessandrino, Ep, Locatelli, F, Visani, G, Di Bartolomeo, P, Papineschi, Federico, Favre, C, Iori, Ap, Foà, R, Locasciulli, A, Majolino, I, Majolino, P, Leone, G, Arcese, W, Cerretti, R, Carella, Am, Cascavilla, N, Lauria, F, Mazza, P, Cerno, M, and Benedetti, F.

Published
2009

38. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome : a study from the Gruppo Italiano Trapianto di Midollo Osseo(GITMO)

Author

Alessandrino, Ep, Della Porta MG, Bacigalupo, A, Van Lint MT, Falda, M, Onida, F, Bernardi, M, Iori, Ap, Rambaldi, A, Cerretti, R, Marenco, P, Pioltelli, P, Malcovati, L, Pascutto, C, Oneto, R, Fanin, R, Bosi, A, Collaboratori Levis, A, Bandini, G, Casini, M, Rossi, G, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Guidi, S, Corradini, P, Milani, R, Morra, E, Lambretenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scimè, R, Iannitto, E, Musso, M, Locatelli, F, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, F, Messina, G, Gugliotta, L, Foà, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, Benedetto, Boccadoro, Mario, Cerno, M, and Raimondi, R.

Subjects
Adult, Male, medicine.medical_specialty, Blood transfusion, Adolescent, medicine.medical_treatment, Immunology, World Health Organization, Biochemistry, Gastroenterology, Humans, Myelodysplastic Syndromes, Prognosis, Aged, Recurrence, Survival Rate, Classification, Blood Transfusion, Hematopoietic Stem Cell Transplantation, Middle Aged, Female, Refractory, hemic and lymphatic diseases, Internal medicine, medicine, Survival rate, Acute leukemia, Hematology, business.industry, Cancer, Cell Biology, medicine.disease, Surgery, Transplantation, Who classification, business, Settore MED/15 - Malattie del Sangue
Abstract

We evaluated the impact of World Health Organization (WHO) classification and WHO classification–based Prognostic Scoring System (WPSS) on the outcome of patients with myelodysplastic syndrome (MDS) who underwent allogeneic stem cell transplantation (allo-SCT) between 1990 and 2006. Five-year overall survival (OS) was 80% in refractory anemias, 57% in refractory cytopenias, 51% in refractory anemia with excess blasts 1 (RAEB-1), 28% in RAEB-2, and 25% in acute leukemia from MDS (P = .001). Five-year probability of relapse was 9%, 22%, 24%, 56%, and 53%, respectively (P < .001). Five-year transplant-related mortality (TRM) was 14%, 39%, 38%, 34%, and 44%, respectively (P = .24). In multivariate analysis, WHO classification showed a significant effect on OS (P = .017) and probability of relapse (P = .01); transfusion dependency was associated with a reduced OS (P = .01) and increased TRM (P = .037), whereas WPSS showed a prognostic significance on both OS (P = .001) and probability of relapse (P < .001). In patients without excess blasts, multilineage dysplasia and transfusion dependency affected OS (P = .001 and P = .009, respectively), and were associated with an increased TRM (P = .013 and P = .031, respectively). In these patients, WPSS identified 2 groups with different OS and TRM. These data suggest that WHO classification and WPSS have a relevant prognostic value in posttransplantation outcome of MDS patients.

Published
2008

39. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Author

Alessandrino, Ep, Della Porta MG, Bacigalupo, A, Van Lint MT, Falda, M, Onida, F, Bernardi, M, Iori, Ap, Rambaldi, A, Cerretti, R, Marenco, P, Pioltelli, P, Malcovati, L, Pascutto, C, Oneto, R, Fanin, R, Bosi, A, Gruppo Italiano Trapianto di Midollo Osseo, Levis, A, Bandini, G, Casini, M, Rossi, G, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Guidi, S, Corradini, P, Milani, R, Morra, E, Lambretenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scimè, R, Iannitto, E, Musso, M, Locatelli, F, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Gugliotta, L, Foà, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Cerno, M, and Raimondi, R.

Published
2008

42. Current Outcome Of HLA Identical Sibling Vs Unrelated DONOR Transplants In Severe Aplastic Anemia : An EBMT Analysis

Author

Bacigalupo, Andrea, primary, Socié, Gérard, additional, Hamljadi, Rose-Marie, additional, Aljurf, Mahmoud, additional, Mashan, A, additional, Kyrcz-Krzemien, Slawomira, additional, Cybicka, A, additional, Sengeloev, H, additional, Unal, Ali, additional, Beelen, Dietrich, additional, Locasciulli, A, additional, Dufour, Carlo, additional, Passweg, Jakob R., additional, Oneto, R, additional, and Marsh, Judith, additional

Published
2013
Full Text
View/download PDF

44. Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation

Author

Gerull, S., primary, Stern, M., additional, Apperley, J., additional, Beelen, D., additional, Brinch, L., additional, Bunjes, D., additional, Butler, A., additional, Ganser, A., additional, Ghavamzadeh, A., additional, Koh, M. B., additional, Komarnicki, M., additional, Kroger, N., additional, Maertens, J., additional, Maschan, A., additional, Peters, C., additional, Rovira, M., additional, Sengelov, H., additional, Socie, G., additional, Tischer, J., additional, Oneto, R., additional, Passweg, J., additional, and Marsh, J., additional

Published
2013
Full Text
View/download PDF

46. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study

Author

Alessandrino, E. P., primary, Porta, M. G. D., additional, Bacigalupo, A., additional, Malcovati, L., additional, Angelucci, E., additional, Van Lint, M. T., additional, Falda, M., additional, Onida, F., additional, Bernardi, M., additional, Guidi, S., additional, Lucarelli, B., additional, Rambaldi, A., additional, Cerretti, R., additional, Marenco, P., additional, Pioltelli, P., additional, Pascutto, C., additional, Oneto, R., additional, Pirolini, L., additional, Fanin, R., additional, and Bosi, A., additional

Published
2009
Full Text
View/download PDF

48. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, ? glutamyl transferase, donor type and cell dose.

Author

Sormani, M P, Oneto, R, Bruno, B, Fiorone, M, Lamparelli, T, Gualandi, F, Raiola, A M, Dominietto, A, Van Lint, M T, Frassoni, F, Bruzzi, P, and Bacigalupo, A

Subjects
COMPLICATIONS from organ transplantation, MORTALITY, GRAFT versus host disease, HEMATOPOIETIC stem cell transplantation, CHOLINESTERASES
Abstract

Summary:We have previously described a scoring system for patients undergoing hemopoietic stem cell transplantation (HSCT) based on day +7 blood urea nitrogen (BUN) and serum bilirubin levels. We have revised that scoring system using a formal multivariate approach based on a training phase (305 patients) and a validation phase (217 patients). Day +7 BUN, serum cholinesterase (CHE), total proteins (TP), gamma glutamyl transferase (?GT), donor type and cell dose at transplant were included in the new score. The score distribution identified three groups of patients in the training set (<25, 25-75, >75 percentile of the score) which were classified as low, intermediate and high risk. Their actuarial risk of transplant-related mortality (TRM) at 6 years was, respectively, 12, 38 and 60%. In the validation set the 6 year actuarial TRM was, respectively, 15, 40 and 69%. High risk patients had more graft-versus-host disease (GvHD) (P<0.0001) and lower platelet counts (P<0.0001). This study confirms that GvHD and TRM can be predicted on day +7 after HSCT: pre-emptive GvHD therapy may be one option for high-risk patients and is being tested in a prospective randomized trial. The score for single patients can be calculated on the web site http://213.26.110.20/lrm/day_seven_score.html.Bone Marrow Transplantation (2003) 32, 205-211. doi:10.1038/sj.bmt.1704085 [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

49. SURVIVAL IMPROVEMENT OF UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH REDUCED INTENSITY REGIMENS IN HIGH-RISK PATIENTS FOR AGE OR DISEASE (ON BEHALF OF GITMO)

Author

Rambaldi, A., Carobbio, A., Lombardini, L., Teresa Lamparelli, Pollichieni, S., Oneto, R., Fanin, R., Bonifazi, F., Corradini, P., Lambertenghi, G., Ciceri, F., Alessandrino, P. E., Iacopino, P., Arcese, W., Scime, R., Falda, M., Benedetti, F., Bacigalupo, A., Bosi, A., Rambaldi, A, Carobbio, A, Lombardini, L, Lamparelli, T, Pollichieni, S, Oneto, R, Fanin, R, Bonifazi, F, Corradini, P, Lambertenghi, G, Ciceri, Fabio, Alessandrino, Pe, Iacopino, P, Arcese, W, Scime, R, Falda, M, Benedetti, F, Bacigalupo, A, and Bosi, A.

Catalog

Books, media, physical & digital resources
See catalog results